CTOs on the Move

InterVenn

www.intervenn.com

 
InterVenn Biosciences utilizes a proprietary high-throughput glycoproteomic interrogation platform using artificial intelligence and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with applications from the Vista suite of solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.intervenn.com
  • 2 Tower Place 5th Floor
    South San Francisco, CA USA 94080
  • Phone: 888.706.1670

Executives

Name Title Contact Details
Jai Chandarana
Director of Information Security Profile
Randolph Barr
Chief Information and Security Officer Profile

Funding

InterVenn raised $34M on 11/16/2020

Similar Companies

San Miguel Technology

San Miguel Technology Llc is a Landenberg, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VisionGate

VisionGate, Inc., is a clinical stage oncology pharmaceutical and diagnostics company with a focus on the early detection and treatment of lung cancer and bronchial dysplasia.

Cygnal Therapeutics

Founded in 2017 by Flagship Pioneering, Cygnal Therapeutics is the first company to build a platform to develop drugs in the field of exoneural biology. Exoneural biology is broadly implicated in human health and disease. Fueled by our dynamic Exoneural Medicine Platform™, we are creating new medicines across multiple therapeutic areas, starting with cancer and inflammatory diseases.

Elevation Oncology

Elevation Oncology is founded on the belief that every patient living with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. We aim to make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of tumor growth. Together with our peers, we work towards a future in which each tumor`s unique genomic test result can be matched with a purpose-built precision medicine to enable an individualized treatment plan for each patient. Our lead candidate, seribantumab, is intended to inhibit tumor growth driven by NRG1 fusions and is currently being evaluated in the Phase 2 CRESTONE study for patients with solid tumors of any origin that have an NRG1 gene fusion.

Lucigen

Located in Middleton, WI, Lucigen delivers innovative products and services to life scientists and manufacturers for the most pressing challenges in research and molecular diagnostics. With a focus on quality, ease-of-use, and affordability, Lucigen strives to make our customer’s research, manufacturing and diagnostic testing successful and cost-efficient.